0.0130USD0.00%Mkt Cap: 68045 USDP/E: —Last update: 2026-05-22
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops differentiated and novel therapies to address the unmet medical needs of patients with cancer in the United States. Its VersAptx b…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap68.05K USD
Enterprise Value-4.37M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-30.07M USD
Revenue/Share—
Last Price0.0130 USD
Fiscal Year EndDec 2024
MR QuarterMar 2025
Employees12
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.02
PEG—
EV/EBITDA0.18
EV/Revenue—
P/S—
P/B0.03
EPS (TTM)-5.79
EPS (Forward)-0.67
52W Range
0.001016% of range0.0740
52W High0.0740 USD
52W Low0.0010 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-1104.04%
ROA-375.69%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-26.13M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-23317.47%
Net Debt-4.44M USD
Net Debt/EBITDA0.18
Balance Sheet
Debt/Equity0.00
Current Ratio1.79
Quick Ratio1.69
Book Value/Sh0.3950 USD
Cash/Share0.8480 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateJan 28, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.5.23M
Float4.75M
Insiders4.11%
Institutions5.25%
Short Interest
Short Ratio0.1d
Short % Float2.72%
Short % Out.2.62%
Shares Short137.20K
Short (prev mo.)191.88K
Technical
SMA 500.0132 (-1.2%)
SMA 2000.0208 (-37.4%)
Beta1.46
S&P 52W Chg28.31%
Avg Vol (30d)2.86K
Avg Vol (10d)420
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—